MedBulletinsAura Celeste
Español
Neurology

Monthly neurology bulletin — November 3, 2026

🎧 Listen to this issueAudio newscast · 6:04 min
Download MP3Send audio via WhatsApp

Period covered: October 9 to November 3, 2026 (since the previous issue of October 8). The month was shaped by MSToronto2026, the joint ACTRIMS-ECTRIMS meeting (Toronto, October 21–23), with phase 3 data for two BTK inhibitors; by the NEJM publication of two Chinese trials that extend thrombectomy to minor strokes and to windows of 24 to 72 hours; and by several regulatory steps in rare neurodegenerative diseases. This issue includes 10 verified items.

Cerebrovascular disease

1. Thrombectomy for minor stroke with large vessel occlusion at risk of deterioration (MILD-MT)

[Clinical trial] [China]
Randomized trial at 26 Chinese centers in patients with anterior-circulation large vessel occlusion, NIHSS below 6 (median 4) and a perfusion profile at high risk of early deterioration, within 24 hours, assigned to thrombectomy plus medical therapy or medical therapy alone. 304 patients were randomized; 300 were included in the modified intention-to-treat analysis (144 in the endovascular group and 156 in the medical-therapy group). In that analysis, mRS 0–1 at 90 days was 69.4% versus 50.0%; early neurological deterioration at 7 days fell from 31.4% to 13.9%. Any intracranial hemorrhage 18.9% versus 6.8%, symptomatic 2.1% versus 1.9%; there was one death, in the thrombectomy group. Presented at ESOC (May 6–8, 2026) and published in NEJM on October 23, 2026, alongside LATE-MT (early deterioration and any intracranial hemorrhage as presented at ESOC).
Why it matters: it provides a randomized signal of benefit in perfusion-selected minor stroke with large vessel occlusion; but 58% had intracranial atherosclerosis (an Asian profile), a device manufacturer (MicroPort NeurTech) co-funded the trial, safety is not limited to symptomatic hemorrhage: any intracranial hemorrhage nearly tripled with thrombectomy and serious procedure-related complications occurred in 19 patients (13.2%) in the endovascular group; in addition, selection requires CT perfusion.

Sources

2. Thrombectomy 24 to 72 hours after onset (LATE-MT)

[Clinical trial] [China]
Randomized trial led from Changhai Hospital (Shanghai) at 35 centers: 336 patients in the intention-to-treat population (168 per group) with anterior large vessel occlusion presenting 24 to 72 hours after onset, with CT perfusion mismatch, assigned to thrombectomy or medical therapy. The 90-day mRS distribution favored thrombectomy (common odds ratio for better outcome 1.74; 95% CI 1.19–2.55), with 48-hour recanalization of 82.4% versus 18.0% as presented at ESOC; at the cost of mortality of 6.0% versus 1.8% and symptomatic hemorrhage of 4.8% versus 0%. Presented at ESOC (May 2026) and published in NEJM on October 23, 2026.
Why it matters: it extends thrombectomy evidence beyond 24 hours, but with excess death and hemorrhage that demands very careful selection; it does not yet change guidelines and needs replication outside China.

Sources

Neurodegenerative disease and cognition

3. FDA grants priority review to AMT-130 gene therapy for Huntington disease

[Regulatory FDA] [United States / Netherlands]
uniQure announced on November 2, 2026 that the FDA accepted, with priority review, its Biologics License Application under the accelerated approval pathway for ifezuntirgene inilparvovec (AMT-130), a single intrastriatal infusion, with a PDUFA target action date of May 1, 2027 according to the company (subject to change) and a tentatively planned advisory committee. The application rests on the 36-month analysis versus a propensity score-matched external control from the Enroll-HD database; according to NeurologyLive, the high dose slowed cUHDRS progression by 75% (p = 0.003) and CSF neurofilament light was 8.2% below baseline. The 36-month result comes from an external-control comparison; the program also included a sham-controlled study in the United States (10 sham controls), which is not the comparator for that analysis. The confirmatory trial will randomize about 200 patients 2:1 versus standard of care.
Why it matters: it would be a disease-modifying therapy for Huntington disease, but the efficacy result comes from few patients compared with an external control, with a high risk of bias, and does not support a causal inference of benefit.

Sources

4. FDA accepts troriluzole resubmission for spinocerebellar ataxia

[Regulatory FDA] [United States]
Biohaven disclosed in an October 22, 2026 Form 8-K that the FDA accepted its resubmitted application for troriluzole after the November 4, 2025 complete response letter, with a goal date in the first quarter of 2027 and a planned advisory committee. The company relies on a 3-year real-world evidence study versus external natural-history controls (50–70% slowing, per the company) and a 1-year placebo-controlled study in which it highlights a fall-risk reduction of more than 50% in the safety analysis.
Why it matters: the FDA has already rejected these data because of external-control bias; without a positive randomized trial, approval remains doubtful.

Sources

5. Clene files for accelerated approval of CNM-Au8 in ALS based on neurofilament

[Regulatory FDA] [United States]
Clene announced on October 19, 2026 that earlier in October it submitted its NDA under the accelerated approval pathway, with plasma neurofilament light as the biomarker. According to NeurologyLive, both randomized trials missed their primary endpoints: RESCUE-ALS (motor unit index; p = 0.43) and the HEALEY platform (disease rate ratio 0.97); the survival signals (HR 0.40–0.41) and a 16% relative reduction in plasma neurofilament at 76 weeks versus participants initially assigned to placebo, in an open-label extension analysis, come from open-label extensions and exploratory analyses reported by the company.
Why it matters: it is a test case for how far the FDA will accept a biomarker as a surrogate in sporadic ALS; on current evidence, there is no basis to promise patients clinical benefit.

Sources

Neuroimmunology and neuromuscular disease

6. Remibrutinib lowers relapses versus teriflunomide in relapsing MS (REMODEL-1 and REMODEL-2)

[Clinical trial] [International]
Two phase 3 trials with 2,007 adults with relapsing MS randomized 1:1 to oral remibrutinib or oral teriflunomide. Annualized relapse rate 0.073 versus 0.112 (−35.2%; p = 0.018) in REMODEL-1 and 0.080 versus 0.116 (−31.2%; p = 0.034) in REMODEL-2; lower annualized T2 lesion activity (0.94 versus 2.71 and 0.82 versus 2.77). ALT above 3 times the upper limit of normal: 2.0% versus 7.4%, with no Hy's law cases on remibrutinib. Presented at MSToronto2026 and published in The Lancet on October 23, 2026.
Why it matters: a BTK inhibitor with fewer ALT elevations than the comparator, but the relapse reduction is smaller than that reported for fenebrutinib against the same comparator (indirect cross-trial comparison), the disability reduction was only nominal and there is no comparison with anti-CD20 antibodies; funded by Novartis.

Sources

7. Fenebrutinib: new data on chronic active lesions in MS, plus further METEOROID analyses in MOGAD

[Congress] [International]
At MSToronto2026 (Roche release of October 21, 2026), the pooled analysis of FENhance 1 and 2 versus teriflunomide showed a 55% reduction in annualized relapse rate, a 16% reduction in 12-week composite confirmed disability progression (p = 0.04) and a 23% reduction in annual brain volume loss; 75% achieved NEDA-3 at almost two years. Slowly expanding lesion volume was reduced by up to 30% in relapsing MS (FENhance) and primary progressive MS (FENtrepid). In METEOROID (MOGAD), exploratory analyses showed numerically better post-relapse recovery with satralizumab than with placebo (median EDSS change at 12 weeks −2 versus −0.5).
Why it matters: the slowly expanding lesion data point to an effect on smoldering chronic inflammation, the main promise of this class, but these are MRI results and analyses from a company release; according to Roche, an FDA decision on satralizumab in MOGAD is expected in January 2027.

Sources

8. FDA approves zilucoplan autoinjector for generalized myasthenia gravis

[Regulatory FDA] [United States / Belgium]
UCB announced on October 16, 2026 the approval of a once-daily autoinjector of zilucoplan, a C5 inhibitor, for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis, as a second self-administration option alongside the prefilled syringe. In a phase 3b study of 31 patients, complete dose delivery was achieved in 99.8% of 449 uses; it will be available in the first quarter of 2027.
Why it matters: it is a convenience improvement, not an efficacy one; the boxed warning for meningococcal infection remains, requiring vaccination and a safety program.

Sources

Cross-cutting

9. Russia: in-hospital stroke mortality falls to 14.1%, with wide regional differences

[Publication] [Russia]
On World Stroke Day (October 29, 2026), the Russian Health Ministry's chief external neurologist, Nikolai Shamalov, stated that stroke is not "getting younger" in Russia and credited the fall in mortality to the network of vascular centers, thrombolysis and thrombectomy. According to ministry data cited in the report, in-hospital mortality was 14.1% in September 2026, versus 15.3% a year earlier, with regions above 20% (Jewish Autonomous Oblast 26.1%, Kamchatka 23.7%).
Why it matters: these are official administrative data, not a peer-reviewed registry, and the attribution of the decline to the center network is the official's own.

Sources

10. Mexico: reported cerebrovascular disease cases rise 11.7% in 2026

[Publication] [Mexico]
Using epidemiological surveillance data from the Health Ministry, 55,742 cases of cerebrovascular disease have been reported in 2026, 11.7% more than in the equivalent period of 2025 (49,906), as reported by the newspaper Por Esto on October 30, 2026.
Why it matters: the increase may reflect more reporting rather than only more cases, and the report gives no data on access to thrombolysis or stroke units; still, it is a reminder of the growing stroke burden in the region.

Sources

Upcoming meetings and dates

Get every issue by email

Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.

← October 13, 2026